Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC).
OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Professor Steven Charlton as Chief Scientific Officer (CSO), effective 1 December 2024. He will take on the role from Dr Ali Jazayeri, who is leaving OMass to pursue other opportunities.
Through UK-Germany Collaborative R&D funding, Exogene is collaborating with the German company Alithea Bio, aiming to accelerate cancer immunotherapy discovery and make it more cost-effective.
CyanoCapture is making significant strides in advancing sustainable carbon capture technologies with its involvement in two major projects. Both initiatives highlight CyanoCapture's commitment to pioneering carbon-negative solutions and driving progress toward a sustainable, low-carbon future.
Infinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announces that it will be presenting three posters on its pioneering cancer vaccine discovery and development, including one that has been recognised as a \u2018top 100\u2019 poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10th November.
In its first major refresh since its establishment in 2018, the BioEscalator is delighted to welcome five leading University of Oxford academics and innovators to its Management Board. Professors Catherine Green OBE, Beth Psaila, Molly Stevens DBE, Krina Zondervan and Peter Callow, Financial Controller of the Medical Sciences Division at the University of Oxford. The Management Board provides a source of expertise for BioEscalator tenants and works to enhance research at the University by building strong links with small life sciences companies.
Nucleome Therapeutics (\u2018Nucleome\u2019 or \u2018the Company\u2019), a biotechnology company using 3D genomics to discover precision medicines for complex diseases, announces today it has entered a research collaboration with Johnson & Johnson*.
Moa Technology is pleased to announce that Lee Sweetlove, Professor of Plant Sciences at the University of Oxford, has joined our team. Professor Sweetlove will be working to further understanding of the novel herbicidal modes of action discovered by Moa, which we are currently developing into safe, effective and affordable solutions to protect harvests from crop-killing weeds.
\u2018Mighty oaks from little acorns grow.\u2019 And so it is with novel herbicide developer Moa Technology, which has grown from four people when it first became a BioEscalator tenant to a company of 85 with research facilities in Oxford and Yorkshire.
Enara Bio today announces the closing of a $32.5M Series B financing supported by a strong syndicate of new and existing biotech investors. The round was co-led by new investors, Pfizer Ventures and M Ventures, with participation from all existing investors, including RA Capital, Samsara BioCapital and SV Health Investors.
OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the candidate nomination of its lead program targeting the melanocortin-2 (MC2) receptor and key appointments to support its progress towards becoming a clinical-stage company.
Alchemab Therapeutics (Alchemab), a pharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that Jane Osbourn, OBE, FMEDSCI, PhD, Alchemab\u2019s Chief Scientific Officer (CSO), has succeeded Young Kwon, PhD as Chief Executive Officer (CEO) and member of the Board.
CardiaTec, a TechBio company employing computational methods to decode the biology behind cardiovascular disease, has secured $6.5M in seed funding led by Montage Ventures with participation from Laidlaw Scholars Ventures, Apex Ventures, and Continuum Health Ventures.
We are excited to welcome Eterna Biologics, a University of Oxford biotech spinout company with a mission to unleash the full potential of RNA medicines. The company aims to enhance global health by expanding the applicability of RNA-targeting medicine to develop treatment for a wide range of human conditions.
Oxford University spin-out Moa Technology has announced excellent results in multi-country field trials of promising new classes of herbicide with novel modes of action recently discovered by the company.
CyanoCapture was selected as one of the two winners of the Green Sciences Incubator challenge, which L'Or\u00e9al organised in collaboration with Genopole and Hello Tomorrow.
![\"A](\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-doses-first-patient-in-phase-i-iia-trial-of-theo-260-in-ovarian-cancer/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n